Gold prices hold sharp gains as soft US jobs data fuels Fed rate cut bets
NEW YORK - Teleflex Incorporated (NYSE:TFX) saw its shares tumble over 21% on Tuesday after the medical technology company reported fourth quarter results that missed revenue expectations and provided weaker-than-anticipated guidance for 2025. The company also announced plans to separate into two publicly traded entities.
Teleflex reported fourth quarter adjusted earnings per share of $3.89, beating analyst estimates of $3.86. However, revenue of $795.4 million fell short of the $813.14 million consensus forecast.
For the full year 2025, Teleflex guided for adjusted earnings per share of $13.95 to $14.35, below Wall Street expectations of $15.23. The company expects adjusted constant currency revenue growth of just 1% to 2% year-over-year.
"In the fourth quarter, we delivered strong double-digit adjusted earnings per share growth," said Liam Kelly, Teleflex’s Chairman, President and CEO. However, he noted softness in the company’s Interventional Urology segment offset strength in other areas.
In a separate announcement, Teleflex revealed plans to split into two independent, publicly traded companies - referred to as "RemainCo" and "NewCo" for now. The company said the separation is expected to simplify operations and increase management focus.
Additionally, Teleflex disclosed it has agreed to acquire substantially all of BIOTRONIK’s Vascular Intervention business, though financial terms were not provided.
The combination of disappointing results, soft guidance, and major strategic shifts appears to have spooked investors, as reflected in the stock’s sharp decline. Teleflex also announced its CFO Thomas Powell will transition to a strategic advisor role, with James Winters taking over as CFO.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.